bioRxiv Science⌕ Search

Biology subjects

Magda, D. P.

Publications and source records attributed to Magda, D. P..

2 recordsLinked to original sources

Engineering Infrared Light Detection in Blind Human Retina Using Ultrasensitive Human TRPV1 Channels

Engineering infrared light sensitivity in the blind human retina could restore visual function in patients with regional retinal degeneration. However, current approaches are complex and contain non-human biological components. Using rational protein design we engineered human TRPV1 channels ({Delta}786-840) with temperature sensitivity shifted from 45 to 41{degrees}C that enabled near-infrared light- induced heat activation of mammalian cells at close to physiological temperatures. When expressed in ganglion cells of human retinal explants, {Delta}786-840 TRPV1 generated robust spiking responses to brief near-infrared light-induced temperature transients. Additionally, increasing intensity of radiation evoked graded responses correlating with increasing firing frequencies. Unlike previous approaches that used non-human TRPV1 channels, which risk immune reactions and a multicomponent system that poses barriers to clinical implementation, this single component human-derived approach eliminates immunogenicity concerns, addressing a major challenge to clinical translation, and allow gene delivery using adeno-associated viral vectors.

bioengineering↗

High-efficiency base editing for Stargardt disease in mice, non-human primates, and human retina tissue

Stargardt disease is a currently untreatable, inherited neurodegenerative disease that leads to macular degeneration and blindness due to loss-of-function mutations in the ABCA4 gene. We have designed a dual adeno-associated viral vector split-intein adenine base-editing strategy to correct the most common mutation in ABCA4 (c.5882G>A, p.G1961E). We optimized ABCA4 base editing in human models, including retinal organoids, iPSC-derived retinal pigment epithelial (RPE) cells, as well as adult human retinal- and RPE/choroid explants in vitro. The resulting gene therapy vectors achieved high levels of gene correction in mutation-carrying mice and in non-human primates, with an average editing of 37% of photoreceptors and 73% of RPE cells in vivo. The high editing rates in primates make way for precise and efficient gene editing in other neurodegenerative ocular diseases.

neuroscience↗